Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 29:7:21-26.
doi: 10.1016/j.eclinm.2019.01.004. eCollection 2019 Jan.

β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease - A Danish Nationwide Study of 1·3 Million Individuals

Anne Orholm Nielsen  1 , Lars Pedersen  2 , Birgitte Fischer Sode  3 , Morten Dahl  1
Affiliations

β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease - A Danish Nationwide Study of 1·3 Million Individuals

Anne Orholm Nielsen et al. EClinicalMedicine. .

Abstract

Background: The possible association between β-adrenoceptor antagonists (β-blockers) and risk of COPD is controversial. The objective of the present study was to test whether β-blocker use is associated with susceptibility to the disease.

Methods: A total of 301,542 new users of β-blockers and 1,000,633 new users of any other antihypertensive drugs aged 30-90 years without any history of COPD hospitalizations were included in the present study and followed in the Danish National Patient Registry for incident admissions for COPD and COPD death between 1995 and 2015. Multiple adjusted cox regression models were used to examine the association between use of β-blockers and COPD hospitalization. Additionally, subgroup analyses based on underlying diseases at baseline or duration of treatment were performed.

Findings: People treated with β-blockers continuously for more than 6 months had a lower risk of COPD hospitalization during follow-up compared to people treated with any other antihypertensive drugs (adjusted hazard ratio [HRadjusted] 0·80, 95% CI 0·79-0·82). Risk of COPD hospitalization was lowered in the groups treated with β-blockers among patients with ischemic heart disease (0·72, 0·69-0·75), cardiac arrhythmias (0·76, 0·72-0·80), asthma (0·69, 0·61-0·79), hypertension (0·91, 0·86-0·96), and diseases of the pulmonary circulation (pulmonary embolism and cor pulmonale) (0·72, 0·59-0·87). All-cause mortality as well as risk of COPD death during follow-up was lower in the group treated with β-blockers compared to the group treated with any other antihypertensive drugs (0·56, 0·53-0·59).

Interpretation: Treatment with β-blockers seems to reduce risk of COPD hospitalization and mortality compared to treatment with any other antihypertensive drugs.

Funding: The Danish Council for Independent Research in Denmark (grant no. 4183-00569B), The Research Foundation of Health Science in Region Zealand (grant no. RSSF2017000661 and no. 15-000342), The Research Foundation of Medical Science (A.P. Møller Foundation, grant no. 16-68), The Research Foundation in memory of King Christian 10th (grant no. 142/2017), Aase & Ejnar Danielsen's Research Foundation (grant no. 10-001946), and Lundbeck Foundation (grant no. R252-2017-1690).

Keywords: Epidemiology; Obstructive pulmonary disease; Pharmacology; β-Blockers.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cumulative risk of COPD hospitalizations.
Fig. 2
Fig. 2
Cumulative risk of all-cause mortality.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. From the “Global Strategy for the Diagnosis, Management and Prevention of COPD” Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. http://goldcopd.org/ [cited 2018 Jun 24]. Available from.
    1. McDonough J.E., Yuan R., Suzuki M. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575. - PMC - PubMed
    1. Hogg J.C. A pathologist's view of airway obstruction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(5):5–7. - PMC - PubMed
    1. Rang H., Dale M., Ritter J., Moore P. 5th ed. Elsevier Churchill Livingstone; 2003. Pharmacology; p. 797s. Bd.
    1. Nielsen A.O., Jensen C.S., Arredouani M.S., Dahl R., Dahl M. Variants of the ADRB2 Gene in COPD: Systematic Review and Meta-Analyses of Disease Risk and Treatment Response. COPD. 2017;14:451–460. - PubMed

LinkOut - more resources